Literature DB >> 18622160

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.

Florian Rieder1, Claudio Fiocchi.   

Abstract

PURPOSE OF REVIEW: Intestinal fibrosis is a potentially serious complication of inflammatory bowel disease and its pathophysiology is still unclear. This review will discuss recent developments relating to sources of fibroblasts in intestinal inflammation, mediators that modulate fibroblast activation and function, as well as new clinical, laboratory, endoscopic and radiological studies aimed at improving diagnosis and management of intestinal fibrosis in inflammatory bowel disease. RECENT
FINDINGS: The fibroblast remains the central cell responsible for intestinal fibrosis in inflammatory bowel disease and transforming growth factor-beta1 is still the most potent pro-fibrogenic cytokine. Novel mediators, however, are being identified that modulate fibroblast function, such as interleukin-13, interleukin-21, galectin-3, osteopontin, Wnt and toll-like receptor ligands, and anti-tumor necrosis factor-alpha agents. New fibroblast sources are being identified, such as fibrocytes, and new mechanisms of fibroblast generation, like epithelial- and endothelial-to-mesenchymal transition. Animal models of intestinal fibrosis are still few, but new ways to induce gut fibrosis are being explored. Serological markers indicating a clinically complicated course that includes intestinal fibrosis are promising and are being tested in adult and pediatric populations, particularly in Crohn's disease. Video capsule endoscopy, the Given Patency capsule, double balloon enteroscopy, and computed tomographic enteroscopy are some of the new modalities being developed to assess the risk and improve the diagnosis of intestinal fibrosis. Novel therapeutic approaches include endoscopic balloon dilatation with conventional and double balloon enteroscopy, and local injection of glucocorticoids and tumor necrosis factor-alpha blockers, showing partial but encouraging success.
SUMMARY: More studies are needed to improve knowledge of the pathophysiology of intestinal fibrosis if better preventive, diagnostic and therapeutic measures are to be expected in the near future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622160     DOI: 10.1097/MOG.0b013e3282ff8b36

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  26 in total

1.  Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery.

Authors:  Manuela G Neuman
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  Themes in fibrosis and gastrointestinal inflammation.

Authors:  Claudio Fiocchi; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

Review 3.  Multidisciplinary management of gastrointestinal fibrotic stenosis in Crohn's disease.

Authors:  Brice Malgras; Karine Pautrat; Xavier Dray; Pierre Pasquier; Patrice Valleur; Marc Pocard; Philippe Soyer
Journal:  Dig Dis Sci       Date:  2014-11-08       Impact factor: 3.199

4.  Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis.

Authors:  Yosuke Abe; Mitsuyuki Murano; Naoko Murano; Eijiro Morita; Takuya Inoue; Ken Kawakami; Kumi Ishida; Takanori Kuramoto; Kazuki Kakimoto; Toshihiko Okada; Ken Narabayashi; Eiji Umegaki; Kazuhide Higuchi
Journal:  Dig Dis Sci       Date:  2011-09-11       Impact factor: 3.199

5.  Eosinophils and IL-33 Perpetuate Chronic Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn's Ileitis.

Authors:  Joanne C Masterson; Kelley E Capocelli; Lindsay Hosford; Kathryn Biette; Eóin N McNamee; Edwin F de Zoeten; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Cheryl Protheroe; James J Lee; Glenn T Furuta
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

6.  Detecting active inflammation and fibrosis in pediatric Crohn's disease: prospective evaluation of MR-E and CT-E.

Authors:  Keith B Quencer; Katherine Nimkin; Mari Mino-Kenudson; Michael S Gee
Journal:  Abdom Imaging       Date:  2013-08

7.  Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis.

Authors:  Silvia Speca; Christel Rousseaux; Caroline Dubuquoy; Florian Rieder; Antonella Vetuschi; Roberta Sferra; Ilaria Giusti; Benjamin Bertin; Laurent Dubuquoy; Eugenio Gaudio; Pierre Desreumaux; Giovanni Latella
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

Review 8.  Eosinophils in infection and intestinal immunity.

Authors:  Simon P Hogan; Amanda Waddell; Patricia C Fulkerson
Journal:  Curr Opin Gastroenterol       Date:  2013-01       Impact factor: 3.287

Review 9.  Role of microRNAs in gastrointestinal smooth muscle fibrosis and dysfunction: novel molecular perspectives on the pathophysiology and therapeutic targeting.

Authors:  Chadalavada Vijay Krishna; Jagmohan Singh; Chellappagounder Thangavel; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-28       Impact factor: 4.052

10.  Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease.

Authors:  Sayuri Sazuka; Tatsuro Katsuno; Tomoo Nakagawa; Masaya Saito; Keiko Saito; Daisuke Maruoka; Tomoaki Matsumura; Makoto Arai; Hideaki Miyauchi; Hisahiro Matsubara; Osamu Yokosuka
Journal:  Dig Dis Sci       Date:  2013-08-22       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.